Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Long-Term Liabilities

3 Months Ended

Mar. 31, 2015

ACCRUED EXPENSES AND LONG-TERM LIABILITIES

Other accrued expenses consisted of the following as of March 31, 2015 and December 31, 2014:



	March 31, 2015		December 31, 2014
Accrued pass-through costs	$	2,476	$	1,043
Facilities realignment accrual	520		517
Self-insurance accruals	524		463
Indemnification liability	875		875
Contingent consideration	633		633
Acquisition related costs	200		1,225
Liabilities held-for-sale	—		2,820
Rent payable	563		348
DOJ settlement	500		500
Accrued interest	323		465
All others	4,718		5,933
	$	11,332	$	14,822

Long-term liabilities consisted of the following as of March 31, 2015 and December 31, 2014:



	March 31, 2015		December 31, 2014
Rent payable	$	305	$	209
Uncertain tax positions	3,307		3,267
Deferred tax liability	2,526		2,525
DOJ settlement (indemnified by RedPath)	2,250		2,500
Liabilities held-for-sale	—		329
Other	344		313
	$	8,732	$	9,143